MediWound Yönetim

Yönetim kriter kontrolleri 0/4

MediWound CEO'su Ofer Gonen, Jun2022 tarihinde atandı, in görev süresi 2.42 yıldır. in toplam yıllık tazminatı $ 1.13M olup, şirket hissesi ve opsiyonları dahil olmak üzere 42.4% maaş ve 57.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.04% ine doğrudan sahiptir ve bu hisseler € 1.77M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 2.3 yıldır.

Anahtar bilgiler

Ofer Gonen

İcra Kurulu Başkanı

US$1.1m

Toplam tazminat

CEO maaş yüzdesi	42.4%
CEO görev süresi	2.4yrs
CEO sahipliği	1.0%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	2.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Ofer Gonen'un ücretlendirmesi MediWound'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$20m
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	US$1m	US$480k	-US$7m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$850k	US$253k	-US$20m

Tazminat ve Piyasa: Ofer 'nin toplam tazminatı ($USD 1.13M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 780.67K ).

Tazminat ve Kazançlar: Ofer şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Ofer Gonen (51 yo)

2.4yrs

Görev süresi

US$1,133,000

Tazminat

Mr. Ofer Gonen, B.Sc. MA Economic & Finance, serves as Chief Executive Officer at MediWound Ltd. since June 30, 2022. He was Chief Executive Officer of Clal Biotechnology Industries Ltd.from March 7, 2017...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ofer Gonen	Chief Executive Officer	2.4yrs	US$1.13m	1.04% € 1.8m
Hani Luxenburg	Chief Financial Officer	1.5yrs	US$244.00k	Veri yok
Yaron Meyer	Executive VP	10.9yrs	US$379.00k	Veri yok
Ety Klinger	Chief Research & Development Officer	10.5yrs	US$479.00k	Veri yok
Lior Rosenberg	Co-Founder	23.8yrs	US$817.00k	Veri yok
Shmulik Hess	COO & Chief Commercial Officer	less than a year	Veri yok	Veri yok
Liron Gal	Executive Director of Manufacturing Science & Technology	less than a year	Veri yok	Veri yok
Barry Wolfenson	Executive Vice President of Strategy & Corporate Development	1.7yrs	Veri yok	Veri yok
Robert Snyder	Chief Medical Officer	1.8yrs	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: M8W 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen Wills	Independent Director	7.5yrs	Veri yok	Veri yok
Nachum Shamir	Executive Independent Chairman	2.3yrs	Veri yok	Veri yok
David Fox	Independent Director	4.6yrs	Veri yok	Veri yok
Vickie Driver	Independent Director	7.5yrs	Veri yok	Veri yok
Samuel Moed	Member of Strategic Advisory Board	2.1yrs	Veri yok	Veri yok
Samuel Rubinstein	Independent Director	1.3yrs	Veri yok	Veri yok
John Lantis	Member of Strategic Advisory Board	2.1yrs	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: M8W 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

MediWound Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

MediWound Ltd., Annual General Meeting, Jul 09, 2024

MediWound Ltd. Appoints Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, Effective December 1, 2023

High number of new and inexperienced directors

High number of new directors

High number of new directors

MediWound Ltd. Announces Formation of Strategic Advisory Board

Recent updates

MediWound Ltd. to Report Q3, 2024 Results on Nov 26, 2024

MediWound Ltd. Announces Phase II Head-To-Head Study Evaluating EscharEx®? vs. Collagenase in Patients with Venous Leg Ulcers

Second quarter 2024 earnings released: US$0.68 loss per share (vs US$0.099 profit in 2Q 2023)

MediWound Ltd. Announces Positive Results from the U.S. NexoBrid Expanded Access Protocol (NEXT)

MediWound Ltd. to Report Q2, 2024 Results on Aug 14, 2024

MediWound Ltd. Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

MediWound Ltd. announced that it expects to receive $24.999994 million in funding from Mölnlycke Health Care AB and other investors

New minor risk - Profitability

MediWound Ltd., Annual General Meeting, Jul 09, 2024

First quarter 2024 earnings released: US$1.05 loss per share (vs US$0.44 loss in 1Q 2023)

MediWound Ltd. to Report Q1, 2024 Results on May 29, 2024

New major risk - Share price stability

Full year 2023 earnings released: US$0.74 loss per share (vs US$3.93 loss in FY 2022)

MediWound Ltd. to Report Q4, 2023 Results on Mar 21, 2024

Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study

Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns

Mediwound Ltd. Announces Publication of Escharex Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.88 loss in 3Q 2022)

MediWound Ltd. Appoints Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, Effective December 1, 2023

MediWound Ltd. to Report Q3, 2023 Results on Nov 21, 2023

MediWound Ltd Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

MediWound Ltd. Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army

MediWound Ltd. Announces U.S. Commercial Availability of NexoBrid®? for the Treatment of Severe Thermal Burns in Adults

High number of new and inexperienced directors

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: US$0.099 (vs US$0.92 loss in 2Q 2022)

MediWound Ltd. to Report Q2, 2023 Results on Aug 15, 2023

MediWound Ltd. Announces Commercial Launch of NexoBrid®? in Japan

Mediwound Ltd. Announces Positive Results in Its U.S. Phase I/Ii Study of Mw005 for the Treatment of Basal Cell Carcinoma

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design

First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.87 loss in 1Q 2022)

MediWound Ltd. to Report Q1, 2023 Results on May 30, 2023

Full year 2022 earnings released: US$3.93 loss per share (vs US$3.48 loss in FY 2021)

MediWound Ltd. Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

MediWound Announces Positive Results in U.S. Phase I/II Study of Mw005 for the Treatment of Basal Cell Carcinoma

MediWound Ltd Gains Marketing Approval of NexoBrid® in India

High number of new directors

MediWound Ltd. to Report Q3, 2022 Results on Nov 15, 2022

High number of new directors

MediWound Ltd. Announces Formation of Strategic Advisory Board

MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022

MediWound Ltd. Announces European Medicines Agency Validates for Review the Type Ii Variation

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 2Q 2021)

Mediwound Ltd. Announces Management Changes

MediWound Announces U.S. FDA Acceptance of Biologics License Application for Nexobrid for the Treatment of Severe Thermal Burns

MediWound Ltd. to Report Q2, 2022 Results on Aug 09, 2022

MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MediWound Ltd. Announces Positive Results from Its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers

MediWound Ltd. Announces Appointment of Tzvi Palash as Chief Operating Officer

MediWound Ltd., Annual General Meeting, Jul 19, 2022

Mediwound Ltd. Appoints Sharon Malka to the Company's Board of Directors

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.10 loss in 1Q 2021)

MediWound Ltd. Announces Positive Results from U.S. Phase 2 Clinical Study of Escharex® for the Debridement of Venous Leg Ulcers

MediWound Ltd. to Report Q1, 2022 Results on May 17, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

U.S. Department of Defense Awards Defense Research Grant to Mediwound Ltd. for the Development of Nexobrid for the U.S. Army

MediWound Ltd. announced that it has received $9 million in funding from Biomedical Advanced Research And Development Authority

Mediwound Announces Positive Topline Results from Its U.S. Phase 2 Trial of Escharex for Debridement of Chronic Wounds

MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds

MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.073 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 2Q 2020)

MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application

MediWound Completes Patient Enrollment for Interim Assessment of U.S. EscharEx Phase 2 Adaptive Design Study

First quarter 2021 earnings released: US$0.10 loss per share (vs US$0.09 loss in 1Q 2020)

Full year 2020 earnings released: US$0.34 loss per share (vs US$0.076 profit in FY 2019)

Revenue beats expectations

MediWound Ltd. Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer

MediWound Ltd. to Report Q4, 2020 Results on Feb 25, 2021